| Title |
Pharmacological treatment of depression in patients with a primary brain tumour
|
|---|---|
| Published in |
Cochrane database of systematic reviews, May 2013
|
| DOI | 10.1002/14651858.cd006932.pub3 |
| Pubmed ID | |
| Authors |
Alasdair G Rooney, Robin Grant |
| Abstract |
This is an updated version of the original Cochrane review published in Issue 3, 2010.Patients with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, these patients are also at high risk of epileptic seizures, cognitive impairment and fatigue, all of which are potential side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in brain tumour patients is unclear. |
Twitter Demographics
The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Norway | 1 | <1% |
| Unknown | 102 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 16% |
| Student > Bachelor | 16 | 15% |
| Student > Doctoral Student | 12 | 12% |
| Researcher | 11 | 11% |
| Student > Ph. D. Student | 7 | 7% |
| Other | 21 | 20% |
| Unknown | 20 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 29% |
| Psychology | 15 | 14% |
| Nursing and Health Professions | 13 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Social Sciences | 4 | 4% |
| Other | 10 | 10% |
| Unknown | 28 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2013.
All research outputs
#18,339,860
of 22,711,242 outputs
Outputs from Cochrane database of systematic reviews
#11,426
of 12,313 outputs
Outputs of similar age
#145,813
of 194,697 outputs
Outputs of similar age from Cochrane database of systematic reviews
#256
of 277 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,313 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,697 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 277 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.